Neuralink valuation surges to $42 billion on Musk investor demand

Investors are valuing Elon Musk's brain-chip startup Neuralink at $42 billion in secondary markets, nearly five times its last official funding round.

The near-trillionaire's brain-computer interface company is commanding a valuation of as much as $42 billion in secondary market transactions, according to correspondence seen by Business Insider and a person familiar with the matter — a nearly fivefold increase from the $9 billion Neuralink raised at just over a year ago.

"Several of our limited partners have been asking to buy Neuralink shares at any price," one venture investor said, reflecting the intense demand for exposure to Musk's private AI and robotics empire.

Transactions in recent months have ranged from $29 billion to $42 billion, with some current bidders attempting to buy shares at an almost $60 billion valuation, according to Caplight, a private markets research provider. The startup has implanted its brain chips in 21 trial patients so far, the company announced earlier this year. Neuralink's most recent publicly announced investment came in May, when the sovereign wealth fund of Oman invested at an undisclosed valuation.

The valuation leap shows that private investors are increasingly willing to pay steep premiums for access to Musk's remaining startups following SpaceX's blockbuster IPO last month, which valued the rocket company at about $1.6 trillion in public markets. For Neuralink, the question is whether its brain-computer interface technology can justify a valuation that rivals established medical device companies before generating meaningful revenue.

The secondary market surge reflects a broader pattern across Musk's private companies. Investors in X and XAI were able to obtain shares in SpaceX through those acquisitions, creating a halo effect that has boosted demand for any Musk-affiliated equity. Neuralink, as one of the few remaining private Musk ventures not yet accessible through public markets, has become a primary beneficiary of that demand.

Yet there is hardly a consensus on where Neuralink should trade. Some investors have balked at the high-priced transactions, according to people familiar with the matter. The startup's official valuation and whether it is raising a new funding round remain unclear. Neuralink did not respond to a request for comment.

Competitive Landscape

Neuralink operates in a small but growing brain-computer interface sector that includes competitors such as Synchron, which has developed a stent-like device that does not require open-brain surgery, and Blackrock Neurotech, which has been implanting devices for over a decade. Unlike Neuralink, which has focused on restoring movement and vision for paralyzed patients, Synchron received FDA approval for human trials in 2021 and has implanted its device in fewer than a dozen patients. The wide valuation gap between Neuralink and its privately held peers reflects Musk's personal premium as much as the underlying technology.

Investment Impact

For investors, Neuralink's valuation surge creates a high bar for future returns. At $42 billion, the startup would rank among the most valuable private neurotechnology companies globally — a multiple that implies billions in future revenue from a device that has not yet received regulatory approval for commercial use. Musk has said the chips could eventually restore eyesight and enable telepathic communication, but those claims remain years from clinical validation. If Neuralink's technology delivers on its promise, early investors could see returns that rival SpaceX's trajectory. If it falters, the $42 billion valuation may prove to be peak Musk premium.

This article is for informational purposes only and does not constitute investment advice.